Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana has slid 10% due to exiting 13 markets, raising investor concerns, but remains attractive due to strong profitability and management alignment with investor interests. Despite trailing the S&P 500, Humana's core profitability is impressive, with NOPAT rising even as GAAP net income declined. Executive compensation tied to ROIC ensures management is incentivized to create value, making Humana a good long-term investment.

Humana's Falling Share Price Gives Investors An Opportunity

HUM collaborates with Evergreen Nephrology to introduce a specialized care program for chronic kidney disease patients.

Humana (HUM), Evergreen Nephrology Partner to Improve Health Outcomes

Humana (HUM) reported earnings 30 days ago. What's next for the stock?

Why Is Humana (HUM) Down 2.1% Since Last Earnings Report?

Humana (NYSE: HUM) currently trades around $355 per share, nearly 30% below its peak level of $495 seen in September 2022. In comparison, UnitedHealth stock (NYSE: UNH) saw its stock rise 13% over the same period.

Can Humana Stock Return To $500 From Its Current Level Of $350?

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), a leading health and well-being company, is proud to announce that it has been named to PEOPLE's “100 Companies That Care list” for 2024, ranking Humana in the top 50 (46th place). The annual list honors companies that “go the extra mile to honor their customers, empower their employees, and make the world a better place.” The rankings are also based on over one million employee survey responses and data from companies representing 7.5.

PEOPLE Magazine Recognizes Humana as one of the Top “100 Companies That Care”

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) announced today that Susan M. Diamond, Chief Financial Officer, will make a presentation to investors at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 8:00 a.m. Eastern time. A live audio webcast of the presentation will be available via Humana's Investor Relations page at humana.com. The company suggests webcast participants sign on approximately 15 minutes in advance of the presentation to allow time to run.

Humana Inc. to Present at 2024 Wells Fargo Healthcare Conference

LOUISVILLE, Ky.--(BUSINESS WIRE)--Inaugural Humana Community Day Promotes Health Benefits of Volunteerism.

Inaugural Humana Community Day Promotes Health Benefits of Volunteerism

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), a leading health and well-being company, launches a refreshed military-connected hiring strategy and earns recognition by U.S. Veterans Magazine as a Top Veteran-Friendly Employer and Top Veteran-Friendly Supplier Diversity Program. Humana administers health benefits for nearly 6 million active-duty military and retirees nationwide and understands the importance of a workforce that reflects the diversity of the military and veteran comm.

Humana Announces New Veteran Hiring Strategy and Recognition as Top Veteran-Friendly Company

Alphabet

Seth Klarman's hedge fund, Baupost Group, cut its position in Google-owner Alphabet in the second-quarter of 2024 while also snapping up a stake in health insurance company Humana, new 13-f filings shows.

Seth Klarman's Baupost Group cuts stake in Alphabet and snaps up Humana

WASHINGTON--(BUSINESS WIRE)--The Trust for the National Mall and Humana Announce New Programming and Advance Court Reservation Sign-up Date for National Mall of Pickleball 2024.

The Trust for the National Mall and Humana Announce New Programming and Advance Court Reservation Sign-up Date for National Mall of Pickleball 2024

LOUISVILLE, Ky.--(BUSINESS WIRE)--The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 42 years, today announced 80 winners of college scholarships awarded through the Humana Foundation Scholarship Program. Scholarships provide up to $3,000 for postsecondary education for children of Humana employees. Annual awards are renewable for up to three years or until completion of a degree or program with a total possible award of $12,000. This year's scholarship recipie.

Humana Foundation Announces 2024 Scholarship Awards

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Urges Shareholders Who Sustained Losses With Humana Inc To Initiate Dialogue

NEW YORK, Aug. 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Humana Inc. (NYSE: HUM) on behalf of long-term stockholders following a class action complaint that was filed against Humana on June 3, 2024 with a Class Period from July 27, 2022, to January 24, 2024. Our investigation concerns whether the board of directors of Humana have breached their fiduciary duties to the company.

HUMANA ALERT: Bragar Eagel & Squire, P.C. is Investigating Humana Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Humana Inc. (“Humana” or the “Company”) (NYSE: HUM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Humana Inc. – HUM

NEW YORK, NY / ACCESSWIRE / August 2, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93651&wire=1 or contact Joseph E. Levi, Esq.

HUM LAWSUIT ALERT: Levi & Korsinsky Notifies Humana Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humana securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period").

FINAL HUM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Humana Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / August 2, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93584&wire=1 or contact Joseph E. Levi, Esq.

Investors in Humana Inc. Should Contact Levi & Korsinsky Before August 2, 2024 to Discuss Your Rights - HUM

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Humana To Contact Him Directly To Discuss Their Options Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Humana To Contact Him Directly To Discuss Their Options

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humana

NEW YORK, NY / ACCESSWIRE / August 2, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93573&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on Humana Inc. (HUM) Should Contact Levi & Korsinsky About Pending Class Action - HUM

NEW YORK , Aug. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humana Inc. ("Humana" or the "Company") (NYSE: HUM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humana investors who were adversely affected by alleged securities fraud between July 27, 2022 and January 24, 2024.

Humana Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 2, 2024 to Discuss Your Rights - HUM

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93455&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Humana Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 2, 2024 – HUM

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93438&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Humana Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 2, 2024 - HUM

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93422&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Humana Inc. (HUM) - August 2, 2024 Deadline to Join – Contact Levi & Korsinsky

NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humana Inc. ("Humana" or the "Company") (NYSE: HUM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Humana Inc. - HUM

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93400&wire=1 or contact Joseph E. Levi, Esq.

News for Humana Stock (HUM)